Struggling drugmaker Alkermes buys Boston biotech

Alkermes (Nasdaq: ALKS) announced Monday that it would pay $100 million upfront and up to $850 million in milestone payments to acquire Atlas Venture-founded startup Rodin Therapeutics.   Through the deal, Alkermes will expand its pipeline outside of psychiatric disorders and acquire drug candidates for Alzheimer’s disease, Huntington’s disease, frontotemporal dementia and depression. Rodin, which launched in 2013 and is based in Boston, began testing its drugs in humans last year, according…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news